9BQJ image
Deposition Date 2024-05-10
Release Date 2024-09-11
Last Version Date 2025-05-21
Entry Detail
PDB ID:
9BQJ
Title:
RO76 bound muOR-Gi1-scFv16 complex structure
Biological Source:
Source Organism:
Homo sapiens (Taxon ID: 9606)
Mus musculus (Taxon ID: 10090)
Host Organism:
Method Details:
Experimental Method:
Resolution:
3.30 Å
Aggregation State:
PARTICLE
Reconstruction Method:
SINGLE PARTICLE
Macromolecular Entities
Polymer Type:polypeptide(L)
Molecule:Guanine nucleotide-binding protein G(i) subunit alpha-1
Gene (Uniprot):GNAI1
Chain IDs:D (auth: A)
Chain Length:354
Number of Molecules:1
Biological Source:Homo sapiens
Polymer Type:polypeptide(L)
Molecule:Guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-1
Gene (Uniprot):GNB1
Chain IDs:A (auth: B)
Chain Length:344
Number of Molecules:1
Biological Source:Homo sapiens
Polymer Type:polypeptide(L)
Molecule:Guanine nucleotide-binding protein G(I)/G(S)/G(O) subunit gamma-2
Gene (Uniprot):GNG2
Chain IDs:B (auth: C)
Chain Length:71
Number of Molecules:1
Biological Source:Homo sapiens
Polymer Type:polypeptide(L)
Molecule:Mu-type opioid receptor
Gene (Uniprot):Oprm1
Chain IDs:C (auth: D)
Chain Length:356
Number of Molecules:1
Biological Source:Mus musculus
Polymer Type:polypeptide(L)
Molecule:scFv16
Chain IDs:E
Chain Length:259
Number of Molecules:1
Biological Source:Mus musculus
Ligand Molecules
Primary Citation
Signaling Modulation Mediated by Ligand Water Interactions with the Sodium Site at mu OR.
Acs Cent.Sci. 10 1490 1503 (2024)
PMID: 39220695 DOI: 10.1021/acscentsci.4c00525

Abstact

The mu opioid receptor (μOR) is a target for clinically used analgesics. However, adverse effects, such as respiratory depression and physical dependence, necessitate the development of alternative treatments. Recently we reported a novel strategy to design functionally selective opioids by targeting the sodium binding allosteric site in μOR with a supraspinally active analgesic named C6guano. Presently, to improve systemic activity of this ligand, we used structure-based design, identifying a new ligand named RO76 where the flexible alkyl linker and polar guanidine guano group is swapped with a benzyl alcohol, and the sodium site is targeted indirectly through waters. A cryoEM structure of RO76 bound to the μOR-Gi complex confirmed that RO76 interacts with the sodium site residues through a water molecule, unlike C6guano which engages the sodium site directly. Signaling assays coupled with APEX based proximity labeling show binding in the sodium pocket modulates receptor efficacy and trafficking. In mice, RO76 was systemically active in tail withdrawal assays and showed reduced liabilities compared to those of morphine. In summary, we show that targeting water molecules in the sodium binding pocket may be an avenue to modulate signaling properties of opioids, and which may potentially be extended to other G-protein coupled receptors where this site is conserved.

Legend

Protein

Chemical

Disease

Primary Citation of related structures